{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-000057","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2026-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.102874+00:00","generated_at":"2026-05-16T11:48:12.354825+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ironwood issues FY 2026 guidance; LINZESS net sales targeted at $1.125-1.175B","bullets":["FY 2026 LINZESS U.S. net sales guided at $1.125B-$1.175B; total revenue $450M-$475M.","FY 2026 adjusted EBITDA expected >$300M; FY 2025 guidance maintained at >$135M.","Ended Q4 2025 with >$200M cash; LINZESS list price reduced effective Jan 1, 2026.","FDA aligned on confirmatory Phase 3 trial design for apraglutide (SBS-IF); trial to start H1 2026.","Strategic alternatives review ongoing to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-000057","json":"https://secwatch.observer/filing/0001104659-26-000057.json","markdown":"https://secwatch.observer/filing/0001104659-26-000057.md","text":"https://secwatch.observer/filing/0001104659-26-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465926000057/0001104659-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465926000057/tm2534554d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:48:12.354825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}